In the case of non-small cell lung cancer, BDNF treatment has been shown to counteract cisplatin-induced cell death and reduce the chemosensitivity of neuroblastoma cells to cisplatin, with a role of PI3K implicated in BDNF's effects (Ray et al. 2022). This evidence concerns the gene BDNF and non-small cell lung carcinoma.